Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication Ibrance, according to the Centers for Medicare & Medicaid Services (CMS).
Gabapentin has soared in popularity as an alternative to opioids, but research is finding that it isn’t as safe or effective ...
In a significant move, the Trump administration announced agreements with major drug manufacturers Eli Lilly and Novo Nordisk on November 6, 2025. These agreements aim to reduce the cost of popular ...
For some GLP-1 users, the road from slim to grim is short. Surveys show that nearly 12% of Americans have turned to Ozempic, Wegovy or similar drugs to lose weight, with prescriptions more than ...
Ten medications accounted for nearly one-third of 340B program-covered outpatient drugs in 2024, according to a Dec. 11 report. The Health Resources and Services Administration, an HHS agency, ...
The Trump administration has negotiated lower prices for 15 widely used medications covered by Medicare, with the federal government saying the effort will cut spending on those drugs by 44%, or about ...
New drug prices increased by 51% over three years, often exceeding value benchmarks, potentially costing the healthcare system $1.5 billion. Providers worry about medication stocking due to Part B ...
A new study suggests that one of the most common diabetes treatments may speed type 2 diabetes progression by causing insulin-producing cells to lose their functional identity. Sulphonylureas have bee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback